| INTRODUC TI ON
Sideroblastic anemias (SAs) are a heterozygous group of disorders characterized by the presence of ring sideroblasts in the bone marrow. Congenital sideroblastic anemias are syndromic and nonsyndromic and caused by pathogenic variants in genes involved in heme synthesis, Fe-S cluster biogenesis, and mitochondrial protein synthesis. ABCB7, SLC19A2, PUS1, YARS2, TRNT1, mitochondrial DNA, and NDUFB11 genes are responsible so far for syndromic CSA (X-linked SA with spinocerebellar ataxia, thiamine-responsive megaloblastic anemia, myopathy with lactic acidosis and SA, B-cell immunodeficiency with fevers and developmental delay, Pearson marrow-pancreas syndrome). ALAS2, SLC25A38, GLRX5, STEAP3, and HSPA9 genes are responsible so far for nonsyndromic CSA (Xlinked SA or XLSA, autosomal recessive SA). [1] [2] [3] XLSA, OMIM: 300751, is the most common type of nonsyndromic CSA and caused by variants in the erythroid-specific gene coding 5-aminolevulinate synthase (ALAS2) localized on chromosome Xp11.21. ALAS (EC 2.3.1.37) is the first enzyme of heme synthesis and catalyzes the condensation of glycine and succinyl coenzyme A into 5-aminolevulinic acid (ALA) in the mitochondria. [1] [2] [3] XLSA patients present variable degrees of anemia, often mild or asymptomatic, recognized in adulthood or later life. Anemia is typically microcytic and hypochromic with poikilocytosis, red blood cell distribution width is usually increased. Nearly one-third of probands are female where anemia results from an X inactivation skewing and is typically nonmicrocytic. [1] [2] [3] Anemia in many XLSA patients responds variably to supplementation with pyridoxine (vitamin B6) which is converted into pyridoxal 5-phosphate (PLP), the active cofactor essential for ALAS2 activity.
Due to elevated intestinal absorption of iron, patients will present parenchymal iron overload. [1] [2] [3] Here, we report five patients with five different variants in ALAS2 gene. We performed in silico analysis of variants and in vitro study to assess functional consequences of the two novel variants in ALAS2.
| PATIENTS AND ME THODS

| Patients
Hematologists diagnosed patients with SAs based on the presence of ring sideroblasts in the bone marrow aspirate smear. We performed the genetic study in eighteen unrelated patients; some results have yet been published. 4, 5 
| Molecular analysis of genes
Genomic DNA was extracted from peripheral blood samples. Qubit 
| Normal and variant ALAS2 constructions and in vitro expression
Variant ALAS2 constructs were made by PCR site-directed mutagenesis using the normal ALAS2 construct and in vitro expression of normal and mutant ALAS2 was made as we described in Mendez et al. 4 The variants c.485A>G, c.971T>C, and c.1094A>G were introduced with the following sense oligonucleotides, the nucleotide change is underlined: GGATCACACCTGCCGTGTGTTCAAG, CCCTAAGATACCCAAAACTGTGGCC, and CATGCTGTAGGACTGTG TGGGTCC, respectively, and their antisense oligonucleotides. We 
| HUMARA assay
We performed the human androgen receptor gene polymorphism on genomic DNA from peripheral blood samples of female patients 1, 4, and 5, and the daughter and son of patient 5, to assess the X chromosome inactivation we described in Mendez et al. 
| In silico analysis of ALAS2 variants
Computational analyses were used to predict the effect of the missense substitutions on the ALAS function. The in silico programs used are described in Table 2 . SAs. 9, [12] [13] [14] Moreover, normocytic female patients have also been described. 15 In summary, the genetic study should be recommended to patients with microcytic, macrocytic, or normocytic anemia with ring Novel variants in this study are in bold. n.p., not performed. The in vitro residual activity was calculated as 100 x (SA-SApkk223-3)/(SApkk-ALAS2 -SApkk223-3). In silico predictions, scores in parenthesis. SIFT: score >0.05 indicative of tolerated substitution, score ≤0.05 indicative of not tolerated or deleterious substitution. Mutation Taster: disease-causing (probably deleterious), disease-causing automatic (known to be deleterious), polymorphism (probably harmless), and polymorphism automatic (known to be harmless). Scores may range from 0.0 to 215: a lower score predicts toleration; a higher score predicts nontoleration. Polyphen2: score from 0 to 0.14 benign, from 0.15 to 0.84 possible damaging, and from 0.85 to 1 probably damaging substitutions. CADD: recommended pathogenicity threshold >20. M-CAP: recommended pathogenicity threshold >0.025.
| RE SULTS AND D ISCUSS I ON
sideroblasts. The final diagnosis of patients would allow a more specific therapeutic possibility and mandatory genetic counseling. 
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